Successful Treatment of Anal and Perianal Condyloma Acuminata with Imiquimod

Tawada, Chisato; Oshitani, Yoko; Kimura, Masaki; Seishima, Mariko

doi:10.2340/00015555-1636

Cited by 4 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12,13,[15][16][17][18]20,21 Despite a large number of publications on imiquimod efficacy in the treatment of external genital and perianal warts, [22][23][24][25] safety and efficacy data for the treatment of intra-anal condylomas has rarely been evaluated. 14,20,26 Furthermore, data regarding the tolerability profile of topical imiquimod for treating anal HPV-associated pathology are also very limited. Reported adverse events (AEs) are mainly local pain, itching/burning sensation and bleeding, but systemic AEs such as fatigue or flu-like syndrome can also occur.…”

Section: Introductionmentioning

confidence: 99%

The effectiveness and tolerability of imiquimod suppositories to treat extensive intra-anal high-grade squamous intraepithelial lesions/warts in HIV-infected individuals

et al. 2019

View full text Add to dashboard Cite

Topical imiquimod is a potential treatment for intra-anal condyloma and squamous intraepithelial lesions caused by human papillomavirus (HPV). We aimed to assess the effectiveness and tolerability of imiquimod suppositories for the treatment of anal high-grade intraepithelial lesions (HSIL) and condylomas in HIV-infected patients. We conducted a retrospective analysis in a prospectively followed cohort. High-resolution anoscopy was used for diagnosis and assessment following treatment. Patients’ tolerability was assessed with a self-administered survey. Ninety-five patients (94.7% men) were analyzed. All were on combination antiretroviral therapy. Median CD4 T-cell count was 690 cells/µL, 89% had undetectable plasma viral load. Response to imiquimod was seen in 46.3% (complete: 12.5%, partial: 33.8%) in the intent-to-treat analysis, and in 55.2% (complete: 14.9%, partial: 40.3%) in the on-treatment analysis. Higher response rates were observed for anal condyloma compared with HSIL. A significantly poorer response rate was observed in smokers and in individuals with lower nadir CD4 T-cell counts. Imiquimod tolerability was “good” in 57.1% (n = 36), “acceptable” in 33.3% (n = 21), and “poor” in 9.5% (n = 6). Systemic side effects were reported in 20.7% (n = 13). There was no association between treatment effect and tolerability. In conclusion, imiquimod stands as a well-tolerated option for the treatment of HPV-associated intra-anal pathology in HIV-infected individuals.

show abstract

Section: Introductionmentioning

confidence: 99%

The effectiveness and tolerability of imiquimod suppositories to treat extensive intra-anal high-grade squamous intraepithelial lesions/warts in HIV-infected individuals

et al. 2019

View full text Add to dashboard Cite

show abstract

“…im Verlauf eine Dosisreduktion vorzunehmen und um zu verhindern, dass die Patientin das Präparat falsch anwendet bzw. vorzeitig die Therapie abbricht [12].…”

Section: Tipp Für Die Pr a Xisunclassified

Benigne Veränderungen der Vulva

Beckmann¹,

Abel²,

Koch³

et al. 2018

Frauenheilkunde up2date

View full text Add to dashboard Cite

“…Immunotherapeutic methods are promising for refractory cutaneous warts , especially in cases of multiple lesions or lesions at inaccessible sites. Imiquimod, a unique toll‐like receptor agonist approved by the FDA , has turned out to be a strong adjuvant for reversing the anti‐inflammatory effect of HPV and promoting a strong specific cytotoxic T cell response . Imiquimod holds promise for the treatment of HPV generated lesions.…”

Section: Introductionmentioning

confidence: 99%

Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses

Shi

Luo

Zhang

et al. 2018

Journal of Biophotonics

View full text Add to dashboard Cite

Refractory cutaneous warts are difficult to eliminate. In situ photo-immunotherapy (ISPI) is an innovative treatment concept combining local photothermal therapy (PTT) and topical immunotherapy using imiquimod. To compare the efficacy of ISPI vs topical imiquimod alone, a prospective randomized controlled trial was performed with patients suffering from refractory cutaneous warts. In both groups, approximately 50% of the skin surface containing warts was treated for 6 weeks. On the basis of topical imiquimod, ISPI includes an additional 808 nm laser irradiation. Treatment response, temperatures during irradiation and histopathologic examination were evaluated. The complete response rate in the ISPI-group (22/36, 61.1%) was significantly higher than in the imiquimod alone group (11/34, 32.4%). In the ISPI-group, the mean maximum temperature was 44.5 ± 5.1°C, and obvious lymphocytic infiltration was found in the perivasculature of the dermis. There was no recurrence or worsening in both groups during the 12-month follow-up. No obvious adverse reaction was observed. This study demonstrates that ISPI can be used as an effective and safe treatment modality for refractory cutaneous warts.

show abstract

Successful Treatment of Anal and Perianal Condyloma Acuminata with Imiquimod

Cited by 4 publications

References 10 publications

The effectiveness and tolerability of imiquimod suppositories to treat extensive intra-anal high-grade squamous intraepithelial lesions/warts in HIV-infected individuals

The effectiveness and tolerability of imiquimod suppositories to treat extensive intra-anal high-grade squamous intraepithelial lesions/warts in HIV-infected individuals

Benigne Veränderungen der Vulva

Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses

Contact Info

Product

Resources

About